Madison Irwin, PharmD, BCPS

Chronic pain is associated with a significant financial burden, with an estimated cost placed at $650 billion annually in the US.

A discussion on the new nonopioid selective NaV1.8 pain signal inhibitor with Madison Irwin, PharmD, BCPS.

Madison Irwin, PharmD, BCPS, discusses the importance of suzetrigine’s approval in the pain management space and potential challenges or barriers in its adoption.

A conversation with Madison Irwin, PharmD, BCPS, clinical pharmacist specialist in palliative care at University of Michigan Health and a clinical assistant professor at the University of Michigan College of Pharmacy.

Madison Irwin, PharmD, BCPS, discusses her career pharmacy and how she thinks high rates of chronic pain will impact the field in the coming years.